These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. The RhoB small GTPase in physiology and disease. Vega FM, Ridley AJ. Small GTPases; 2018 Sep 03; 9(5):384-393. PubMed ID: 27875099 [Abstract] [Full Text] [Related]
13. A current overview of RhoA, RhoB, and RhoC functions in vascular biology and pathology. Eckenstaler R, Hauke M, Benndorf RA. Biochem Pharmacol; 2022 Dec 03; 206():115321. PubMed ID: 36306821 [Abstract] [Full Text] [Related]
14. Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization. Tillement V, Lajoie-Mazenc I, Casanova A, Froment C, Penary M, Tovar D, Marquez R, Monsarrat B, Favre G, Pradines A. Exp Cell Res; 2008 Sep 10; 314(15):2811-21. PubMed ID: 18590726 [Abstract] [Full Text] [Related]
15. RhoB can adopt a Mg2+ free conformation prior to GEF binding. Soundararajan M, Turnbull A, Fedorov O, Johansson C, Doyle DA. Proteins; 2008 Jul 10; 72(1):498-505. PubMed ID: 18393397 [No Abstract] [Full Text] [Related]
16. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Wheeler AP, Ridley AJ. Exp Cell Res; 2004 Nov 15; 301(1):43-9. PubMed ID: 15501444 [Abstract] [Full Text] [Related]
17. Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies. Shukla GS, Krag DN, Peletskaya EN, Pero SC, Sun YJ, Carman CL, McCahill LE, Roland TA. Cancer Immunol Immunother; 2013 Aug 15; 62(8):1397-410. PubMed ID: 23736951 [Abstract] [Full Text] [Related]
18. The Role of RhoA, RhoB and RhoC GTPases in Cell Morphology, Proliferation and Migration in Human Cytomegalovirus (HCMV) Infected Glioblastoma Cells. Tseliou M, Al-Qahtani A, Alarifi S, Alkahtani SH, Stournaras C, Sourvinos G. Cell Physiol Biochem; 2016 Aug 15; 38(1):94-109. PubMed ID: 26741994 [Abstract] [Full Text] [Related]
20. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. Lehmann A, Wixted JH, Shapovalov MV, Roder H, Dunbrack RL, Robinson MK. MAbs; 2015 Aug 15; 7(6):1058-71. PubMed ID: 26337947 [Abstract] [Full Text] [Related] Page: [Next] [New Search]